Stryker Corporation 10-Q Summary: Period Ended June 30, 2007
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2007, and the six-month period ended on that date. Stryker Corporation is a leading medical technology company with operations in two primary segments: Orthopaedic Implants and MedSurg Equipment. The company operates globally, with domestic sales accounting for approximately 64% of total revenues in the first half of 2007. Notable corporate actions during the period include the completed sale of its outpatient physical therapy business, Physiotherapy Associates, and the adoption of FASB Interpretation No. 48 regarding uncertainty in income taxes.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2007 | Six Months Ended June 30, 2007 |
|---|---|---|
| Net Sales | $1,463.7 | $2,889.2 |
| Gross Profit | $1,019.4 | $2,005.5 |
| Gross Margin | 69.6% | 69.4% |
| Operating Income | $314.9 | $637.1 |
| Net Earnings (Continuing Ops) | $240.1 | $481.9 |
| Net Earnings (Total) | $269.1 | $512.6 |
| Diluted EPS (Continuing Ops) | $0.58 | $1.16 |
| Diluted EPS (Total) | $0.65 | $1.23 |
| Cash from Operations | $210.9 | $363.6 |
| Cash and Cash Equivalents | $170.0 (as of June 30, 2007) | |
| Marketable Securities | $1,610.2 (as of June 30, 2007) | |
| Long-Term Debt (Current Maturities) | $17.4 (as of June 30, 2007) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% in the second quarter and 15% in the first half of 2007 compared to the prior year periods. Growth was driven by increased unit volume and product mix, with a favorable 2% impact from foreign currency exchange rates.
- Profitability: Net earnings from continuing operations rose 13% in the quarter and 35% in the six-month period. Gross margins improved slightly due to manufacturing efficiencies and lower royalty costs.
- Discontinued Operations: The company recorded a $25.7 million net gain on the sale of Physiotherapy Associates in the second quarter. This divestiture removed the outpatient physical therapy business from the consolidated results.
- Impairment Charges: A $19.8 million charge was recorded in the second quarter for intangible asset impairment related to intervertebral body fusion cage patents, following an FDA decision to downgrade certain products.
- Working Capital: Working capital increased to $3,022.4 million. Days sales outstanding increased to 58 days, and days sales in inventory increased to 149 days, attributed to inventory buildup for anticipated product launches.
Guidance, Outlook, and Risks
- 2007 Outlook: Management projects diluted net earnings per share from continuing operations for 2007 to approximate $2.37, a 27% increase over 2006. Adjusted diluted EPS (excluding impairment and R&D charges) is projected at $2.40.
- Sales Forecast: The company forecasts a constant currency net sales increase of 12% to 13% for 2007, an upward revision from the previous 11% to 13% range.
- Currency Impact: If exchange rates hold near June 30 levels, the company anticipates a favorable impact of 1.0% to 2.0% on full-year net sales.
- Risks and Contingencies:
- Legal Proceedings: The company is cooperating with Department of Justice investigations regarding consulting contracts with surgeons and potential antitrust violations related to orthopaedic implants.
- Regulatory: Risks include potential delays in FDA approvals for new products (e.g., OP-1, FlexiCore) and regulatory actions affecting existing product lines.
- Market Conditions: Pricing pressures from cost-containment measures and changes in reimbursement levels from third-party payors remain key risks.
Investor Verification Checklist
- Impairment Impact: Verify the long-term strategic impact of the $19.8 million write-off on intervertebral body fusion cage patents and the FDA's class II downgrade decision.
- Discontinued Operations: Confirm the final settlement of liabilities related to the Physiotherapy Associates sale, specifically regarding the Department of Justice billing investigation.
- Inventory Levels: Monitor the elevated days sales in inventory (149 days) to ensure it aligns with actual product launch schedules and does not indicate future obsolescence.
- Legal Exposure: Track the status of the Department of Justice subpoenas regarding antitrust laws and surgeon remuneration agreements.
- Non-GAAP Reconciliations: Review the reconciliation of adjusted EPS to ensure the exclusion of the impairment charge and prior-year R&D write-offs accurately reflects core operational performance.